Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg,
10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of
Parkinson's disease patients